ReviewInternational journal of urology : official journal of the Japanese Urological Association2018
Current treatment strategies for advanced prostate cancer.
Review in International journal of urology : official journal of the Japanese Urological Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
135 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review.PloS one · 2018Pooled it
- Detecting disease associated biomarkers by luminescence modulating phages.Scientific reports · 2022Trial
- Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2019Trial
- Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?Medicine · 2019Trial
- Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study.Medical oncology (Northwood, London, England) · 2019Trial
- From fungus fighter to cancer slayer: itraconazole as a multifaceted candidate for drug-resistant prostate cancer.Prostate cancer and prostatic diseases · 2026Review
- Icariin suppresses glycolysis in prostate cancer by upregulating ALKBH5 to mediate EARS2 mJournal of molecular histology · 2026Article
- Preclinical Evaluation of Radium-223 and Immune Checkpoint Inhibitors Using an Immune-Competent Model of Prostate Cancer Bone Metastases.Precision oncology · 2026Article
- A Hybrid compound H93 treats prostate cancer by directly binding UHRF1 and promoting protein dimerization.Communications chemistry · 2025Article
- TOR1 AIP1 interacts with p53 to enhance cell cycle dysregulation in prostate cancer progression.Molecular and cellular biochemistry · 2025Article
- BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways.Cell reports · 2025Article
- From conventional therapy to novel nano-based approaches. A focus on prostate cancer.Nanomedicine (London, England) · 2025Review
- Safety and Efficacy of Reduced Dose of Enzalutamide in Patients with Castration-Resistant Prostate Cancer: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Current Evidence on Cabazitaxel for Prostate Cancer Therapy: A Narrative Review.International journal of urology : official journal of the Japanese Urological Association · 2025Review
- Nanotechnology in prostate cancer: a bibliometric analysis from 2004 to 2023.Discover oncology · 2025Article
- MiRNA expression profiling and clinical implications in prostate cancer across various stages.Scientific reports · 2025Article
- Suppression of dopamine receptor 2 inhibits the formation of human prostate cancer PC‑3‑derived cancer stem cell‑like cells through AMPK inhibition.Oncology letters · 2025Article
- Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan Consortium.International journal of clinical oncology · 2025Article
- 5hmC-profiles in Puerto Rican Hispanic/Latino men with aggressive prostate cancer.Frontiers in oncology · 2025Article
- Autocrine Fibroblast Growth Factor Receptor 1 Signaling Activates Lactate Dehydrogenase A-Aerobic Glycolysis for Advanced Human Prostate Tumor Growth.Prostate cancer · 2025Article
75 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
During the past decade, treatment strategies for patients with advanced prostate cancer involving stage IV (T4N0M0, N1M0 or M1) hormone-sensitive prostate cancer and recurrent prostate cancer after treatment with curative intent, as well as castration-resistant prostate cancer, have extensively evolved with the introduction and approval of several new agents including sipuleucel-T, radium-223, abiraterone, enzalutamide and cabazitaxel, all of which have shown significant improvement on overall survival. The appropriate use of these agents and the proper sequencing of these agents are still not optimized. The results of several recently reported randomized controlled trials and retrospective studies could assist in developing a treatment strategy for advanced prostate cancer. In addition, prospective studies and molecular characterization of tumors to address these issues are ongoing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.